Abstracts Archive - Page 106 of 2607 - ACR Meeting Abstracts

Abstract Number: 1118 • ACR Convergence 2025
Increased Risk of Azathioprine-Induced Leukopenia in Patients with Systemic Lupus Erythematosus: A 10-Year Retrospective Cohort Study at a Quaternary Care Hospital in Thailand
Settawut Buadee¹, Kittikorn Wilasrusmee¹, Tanakrit Kamonsumlitpon¹, Sirirat Charuvanij², Ekapun Karoopongse³ and Praveena Chiowchanwisawakit⁴, ¹Medical Student, Faculty of Medicine, Siriraj Hospital, Mahdol University, Bangkok, Thailand, ²Division of Rheumatology, Department of Pediatrics, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand, ³Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand, ⁴Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand
Background/Purpose: To estimate the incidence and identify associated factors of azathioprine (AZA)-induced leukopenia.Methods: A retrospective cohort study was conducted on 1,062 adult patients with non-malignant…
Abstract Number: 1195 • ACR Convergence 2025
Discordance between Immunoblot and ELISA in the detection of Jo-1 and Ro/Ro-52 Autoantibodies
Antonia Valenzuela¹, Sebastián Andrés Cerda Acevedo² and Francisco Vera Gutiérrez², ¹Pontificia Universidad Catolica de Chile, Santiago, Chile, ²Pontificia Universidad Católica de Chile, Santiago de Chile, Chile
Background/Purpose: Autoantibodies play a key role in the diagnosis, classification, and prognosis of idiopathic inflammatory myopathies (IIM). Among the most relevant are myositis-specific antibodies (MSAs),…
Abstract Number: 1082 • ACR Convergence 2025
Lupus Patient Navigator Program for Improving Care Adherence for Minority Patients
Rashi Vora¹, Samiha Karim², Dulaney Wilson³, Jasvinder Singh⁴, Gary Gilkeson¹, Jim Oates¹ and Diane Kamen⁵, ¹Medical University of South Carolina, Charleston, SC, ²Emory University, Atlanta, GA, ³Medical University of South Carolina, Charleston, ⁴Baylor College of Medicine, Houston, TX, ⁵Medical University of South Carolina, Johns Island, SC
Background/Purpose: Minority patients with systemic lupus erythematosus (SLE) experience a higher disease burden and encounter more barriers to care than White patients, resulting in worse…
Abstract Number: 1155 • ACR Convergence 2025
Zasocitinib (TAK-279), an Investigational, Oral, Allosteric, Selective TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis: Efficacy Analysis by Baseline Characteristics from a Randomized Phase 2b Trial
Nada Elbuluk¹, Melinda J. Gooderham², Jessamyn Blau³, Wenwen Zhang³, Ejim Mark³, Warren Winkelman³ and Mark Lebwohl⁴, ¹Department of Dermatology, USC Keck School of Medicine, Los Angeles, CA, ²SKiN Centre for Dermatology, Queen's University, & Probity Medical Research, Peterborough, ON, ON, Canada, ³Takeda Development Center Americas, Inc., Cambridge, MA, ⁴Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Zasocitinib (TAK-279) is an investigational, highly selective and potent, oral, allosteric tyrosine kinase 2 (TYK2) inhibitor. In a phase 2b trial of moderate-to-severe plaque…
Abstract Number: 1173 • ACR Convergence 2025
Prevalence of Coronary Artery Involvement in IgG4-Related Disease Detected by Non-Gated Cross-Sectional Imaging
Matthew Charles Baker¹, Lauren Taylor², Haziq Siddiqi², Jison Hong² and Brian Pogatchnik², ¹Stanford University, Menlo Park, CA, ²Stanford University, Stanford, CA
Background/Purpose: IgG4-related disease (IgG4-RD) classically presents with a mass or diffusely enlarged organ, but it also affects blood vessels of all sizes. Coronary artery involvement…
Abstract Number: 1167 • ACR Convergence 2025
Clinical Characteristics and Outcomes of IgG4-Related Disease Patients Who Chose Watchful Observation without Treatment Intervention: A Single-Center Study
Kanako Chujo¹, Hiromi Shimada², Shusaku Nakashima², Taichi Miyagi¹, Koichi Sugihara², Yusuke Ushio¹, Mao Mizusaki², Naoto Manabe¹, Mayuko Wada², Risa Wakiya³, Hiroki Ozaki⁴ and Hiroaki Dobashi², ¹Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan, ²Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Kagawa, Japan, ³Division of Rheumatology, Departent of Internal Medicine, Toho University School of Medicine, Tokyo, Japan, ⁴KKR Takamatsu Hospital, Takamatsu, Kagawa, Japan
Background/Purpose: Treatment of IgG4-related disease (IgG4-RD) is recommended for patients with severe organ involvement or for patients with reduced quality of life even in the…
Abstract Number: 1128 • ACR Convergence 2025
Association between leptin levels, body mass index and health-related quality of life in patients with gout
Inna Orlova¹, Iryna Shapoval², Nataliia Shkolina¹, Nataliia Kuzminova¹ and Mykola Stanislavchuk³, ¹National Pirogov Memorial Medical University, Vinnytsya, Vinnytsya, Ukraine, ²National Pirogov Memorial Medical University, Vinnytsya (Ukraine), Vinnytsya, Ukraine, ³National Pirogov Memorial Medical University, Vinnytsia, Vinnytsia, Ukraine
Background/Purpose: Gout is s a disease with a high disability rate, resulting in severe social burden and is associated with reduced health-related quality of life…
Abstract Number: 1016 • ACR Convergence 2025
Association between inflammatory biomarkers and predicted heart failure risk in rheumatoid arthritis
Ilana Usiskin¹, Lauren rusnak², Katherine Zhong³, Ying Qi⁴, Nicole Yang², Gregory McDermott⁵, Brittany Weber⁶ and Katherine Liao², ¹Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital, Boston, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Short Hills, NJ, ⁴Brigham and Women’s Hospital, Boston, ⁵Brigham and Women's Hospital, Brookline, MA, ⁶Brigham and Women's Hospital, DEDHAM, MA
Background/Purpose: Heart failure (HF) is a major cause of morbidity and mortality in rheumatoid arthritis (RA). Prior work has suggested that higher levels of inflammation…
Abstract Number: 1187 • ACR Convergence 2025
Myositis-Specific Antibody Profiles and Factors Associated With Rapidly Progressive Interstitial Lung Disease and Mortality in Antisynthetase Syndrome: A Systematic Review and Meta-Analysis
Tulaton Sodsri¹, Nattanicha Chaisrimaneepan², Ben Thiravetyan³, Rabhas Boonyawairote⁴, Nopavit Mohpichai⁵, Nutchapon Xanthavanij⁶, Natnicha Jakramonpreeya⁷, Pintip Ngamjanyaporn⁸ and Tananchai Petnak⁸, ¹Department of Medicine, Texas Tech University Health Sciences Center, Bangkok, Thailand, ²Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, ³Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, ⁴University of Illinois at Chicago, Chicago, ⁵Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, ⁶Mount Auburn Hospital, Harvard Medical School, Cambridge, ⁷Chakri Naruebodindra Medical Institute, Bangkok, Thailand, ⁸Ramathibodi Hospital, Bangkok, Thailand
Background/Purpose: The associations between various myositis-specific antibodies (MSAs), rapidly progressive interstitial lung disease (RP-ILD), and mortality in antisynthetase syndrome (ASS) have been previously reported in…
Abstract Number: 1182 • ACR Convergence 2025
Cardiac Sarcoidosis in Black Patients: A Biopsy-Confirmed Cohort Study
Roshan Subedi¹, Haya Haddad², Rachel Barish¹, Tania Vora¹, Nana Afari-Armah³, Ajay Kadakkal¹, Farooq Sheikh¹ and Florina Constantinescu¹, ¹Medstar Washington Hospital Center, Washington, DC, ²Medstar Washington Hospital Center, Silver Spring, MD, ³Medstar Washington Hospital Center, Washington
Background/Purpose: Sarcoidosis is an inflammatory disease characterized by non-necrotizing granulomatous inflammation that can affect any organ. Approximately 5% of patients with sarcoidosis develop clinically significant…
Abstract Number: 1078 • ACR Convergence 2025
Trends in Hospitalization rate with Lupus in the State of Florida: A retrospective data review from Florida Health Charts from 1992-2023
Muhammad Sohaib Asghar¹, Mohammed Akram², Veerkaran Banga¹, rajkaran Banga¹, Woo Joo Lee¹, Afsana Ansari Shaik³, Syed Muhammad Muneeb Akhtar⁴ and Thomas Shimshak¹, ¹AdventHealth Sebring, Sebring, FL, ²HCA Aventura, Aventura, FL, ³Mayo Clinic, Rochester, MN, ⁴Dow University of Health Sciences, Karachi, Pakistan
Background/Purpose: Lupus is a systemic autoimmune disease that occurs when the body's immune system attacks its own tissues and organs. This study was conducted to…
Abstract Number: 1129 • ACR Convergence 2025
Effectiveness of sodium-glucose cotransporter type 2 inhibitors and urate-lowering agents in patients with gout: data from a single-center specialised clinic
Jose Doménech Serrano¹, Ivana García Loiseau², Cristina RodrÍguez-Alvear³, Pablo Riesgo Sanchis¹, Oscar Moreno Pérez¹ and Mariano Andrés¹, ¹Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, ²Miguel Hernández University, Alicante, Spain, ³Virgen de la Peña General Hospital, Fuerteventura, Spain
Background/Purpose: Sodium-glucose cotransporter type 2 inhibitors (SGLT2I) proved substantial benefits in diabetes mellitus (DM), heart failure (HF) and kidney disease (KD). In pivotal trials, SGLT2Is…
Abstract Number: 1115 • ACR Convergence 2025
Evaluation Of The Global Toxicity Burden In Patients Treated With Checkpoint Inhibitors Addressed For a Rheumatologic Toxicity And Its Impact On Oncological Outcomes
Juliette quelain¹, Eleonore Mourre², Julien Henry¹, Rakiba Belkir³, Andrew Cope⁴, Debashis Sarker⁵, Yin Wu⁶, Matthaios Kapiris⁷, Aurelien Marabelle⁸, Caroline Robert⁸, Raphaele Seror⁹, Xavier Mariette¹⁰ and Samuel Bitoun¹, ¹APHP, PARIS, France, ²APHP, PARIS, ³PARIS, PARIS, France, ⁴King's College London, London, United Kingdom, ⁵Comprehensive Cancer Centre and Consultant Medical Oncologist at Guy's, St Thomas' and King's College Hospitals., London, United Kingdom, ⁶Honorary Consultant Medical Oncologist at Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, ⁷KCL, LONDON, United Kingdom, ⁸IGR, PARIS, France, ⁹Department of Rheumatology, National referral center for auto immune disease and Sjogren disease, Université Paris-Saclay, INSERM UMR¹¹⁸⁴: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France., le kremlin bicetre, France, ¹⁰Université Paris-Saclay, Le Kremlin Bicetre, France
Background/Purpose: Approvals for immune checkpoint inhibitors (ICIs) have expanded, and triple therapy combining anti-PD-1, anti-CTLA-4, and anti-LAG3 have been evaluated with encouraging results. But they…
Abstract Number: 1194 • ACR Convergence 2025
Risk of Calcinosis with Proton Pump Inhibitor Use in Adult Dermatomyositis and Systemic Sclerosis
Antonia Valenzuela¹, Nicolás González², José Rojas³, Martin Fuentes³, Srijana Davuluri⁴, Brian Lee⁵, David Fiorentino⁶ and Lorinda Chung⁴, ¹Pontificia Universidad Catolica de Chile, Santiago, Chile, ²Pontificia Universidad Católica de Chile, Santiago de Chile, Chile, ³Pontificia Universidad Católica de Chile, Santiago de Chile, Chile, ⁴Stanford University, Stanford, CA, ⁵Stanford University, Stanford, ⁶Department of Dermatology, Stanford University Medical Center, Stanford, CA
Background/Purpose: Calcinosis is a painful, debilitating manifestation in connective tissue diseases. Recent findings suggest a link between proton pump inhibitor (PPI) use and calcinosis in…
Abstract Number: 1193 • ACR Convergence 2025
Lung Transplant Outcomes in Patients with Myositis- and Systemic Sclerosis-Associated Interstitial Lung Disease Compared to Idiopathic Pulmonary Fibrosis: A Multicentric Retrospective Analysis
Angela Chang¹, Navid Saleh¹, Alec Yu¹, Darya S. Jalaledin², Sabrina Hoa³, Robert Levy⁴, Jennifer Wilson⁵, Charles Poirier⁶, John Yee¹, James Choi¹, Océane Landon-Cardinal⁷, Hyein Kim⁸ and Kun Huang⁹, ¹University of British Columbia, Vancouver, BC, Canada, ²Université de Montréal, Saint-Lambert, QC, Canada, ³University of Montreal, Brossard, QC, Canada, ⁴University of British Columbia, Deerfield, IL, ⁵UBC, Vancouver, BC, Canada, ⁶University of Montreal, Montreal, QC, Canada, ⁷Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁸The University of British Columbia, Vancouver, BC, Canada, ⁹University of British Columbia, Vancouver, Surrey, BC, Canada
Background/Purpose: Interstitial lung disease (ILD) is a frequent complication of idiopathic inflammatory myositis (IIM) and systemic sclerosis (SSc), ranging from subclinical ILD to rapidly progressive…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].